Kit for detecting procalcitonin

Abstract

The invention discloses a kit for detecting procalcitonin. The kit comprises a magnetic particle separation reagent, a PCT (procalcitonin) detection antibody, an enzyme conjugate and a luminescent substrate, wherein the protein molecule coupled with the magnetic particles in the magnetic particle separation reagent is goat anti-mouse immunoglobulin G or streptavidin; the PCT detection antibody isa mouse anti-PCT monoclonal antibody; and the enzyme conjugate is a horseradish peroxidase-labeled goat anti-PCT polyclonal antibody. The kit has the beneficial effects of high detection sensitivity and low cost.

Description

technical field [0001] The invention relates to a detection technology for procalcitonin, in particular to a kit for detecting procalcitonin. Background technique [0002] In recent years, the pathological and physiological processes of systemic infection have been better understood, and intensive supportive treatment has also been significantly improved. However, systemic infection and its complications are still the leading cause of death for patients in non-cardiac intensive care units. There are about 500,000 systemic infections in the United States each year, and about 40% of them eventually die. Therefore, there is a need for a marker that can more effectively reflect the degree of inflammatory damage caused by infection. Procalcitonin (PCT) is a new indicator with high sensitivity and specificity. It is significantly elevated when bacterial or fungal infection is combined with severe systemic reactions or organ hypoperfusion, but its level is normal when it is viral ...

AI Technical Summary

Problems solved by technology

[0015] 1. Ordinary plate or tube coating reagents, limited by the coating area, cannot coat more antibodies to participate in the immune reaction, and the reaction process is a diffusion process from liquid to solid, and the immune reaction process is very slow

This immobilization method is difficult to achieve higher analytical sensitivity and cannot achieve rapid detection

[0016] 2. The existing methods basically use luminescent substances to directly label antibodies (luminescent substances such as acridinium esters, isoluminols), direct labeling is likely to reduce the luminous efficiency of luminescent substances, and the stability of luminescent markers is poor

[0017] 3. The existing direct markers of acridinium esters and isoluminol are all instantaneously luminescent, and the luminescence time is extremely short, requiring a complex in-situ detection mechanism, and it is difficult to ensure the repeatability of the results, and there is no advantage in cost

[0018] 4. The method described in the patent CN 101029897A also has the disadvantages of too many markers and complicated reaction process

But whether i

Images